Neoadjuvant chemotherapy for radiation associated angiosarcoma (RAAS) of the breast: A retrospective single center study

Autor: Stijn J.C. van der Burg, Sophie J.M. Reijers, Anke Kuijpers, Lotte Heimans, Astrid N. Scholten, Rick L.M. Haas, Hester van Boven, Willemijn M. Kolff, Marie-Jeanne T.F.D. Vrancken Peeters, Martijn Kerst, Beatrijs A. Seinstra, Neeltje Steeghs, Winette T.A. van der Graaf, Yvonne M. Schrage, Winan J. van Houdt

Publikováno v: Breast, Vol 78, Iss , Pp 103825- (2024)

Background: Radiation associated angiosarcoma (RAAS) of the breast is a rare malignancy with poor survival. Optimal treatment strategies remain uncertain due to a lack of data, and vary between surgery alone and a combination of surgery with (neo)adj

Externí odkaz: https://doaj.org/article/be377ca4956c427e9a36174347517bd4

(Cost-)effectiveness of an individualised risk prediction tool (PERSARC) on patient’s knowledge and decisional conflict among soft-tissue sarcomas patients: protocol for a parallel cluster randomised trial (the VALUE-PERSARC study)

Autor: Cornelis Verhoef, Rick L Haas, Elske M van den Akker-van Marle, Leti van Bodegom-Vos, Michiel A J van de Sande, Ellen G Engelhardt, Perla Marang-van de Mheen, Anouk A Kruiswijk, Yvonne M Schrage, Robert J van Ginkel, Han Bonenkamp, Marc HA Bemelmans, Ibtissam Acem, Stefanie Hakkesteegt, Roos F Bleckman, Marloes van Duijvenbode, Nicolette Leijerzapf, Jos A van der Hage, Robert J.P. van der Wal

Publikováno v: BMJ Open, Vol 13, Iss 11 (2023)

Introduction Current treatment decision-making in high-grade soft-tissue sarcoma (STS) care is not informed by individualised risks for different treatment options and patients’ preferences. Risk prediction tools may provide patients and profession

Externí odkaz: https://doaj.org/article/1bc6e7a42b9748709211f848ccf38441

Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly

Autor: Roos F. Bleckman, Ibtissam Acem, Veroniek M. van Praag, Desirée M.J. Dorleijn, Cornelis Verhoef, Yvonne M. Schrage, Rick M.L. Haas, Michiel A.J. van de Sande, null the collaborative Persarc research group, Han Bonenkamp, Robert J. van Ginkel, Dirk J. Grünhagen, Lee M. Jeys, Johnny Keller, Emelie Styring, Joanna Szkandera, Olga Zaikova

Publikováno v: European Journal of Surgical Oncology, 48(5), 985-993. W.B. Saunders
European Journal of Surgical Oncology, 48, 985-993
European Journal of Surgical Oncology, 48, 5, pp. 985-993
European Journal of Surgical Oncology, 48(5), 985-993. ELSEVIER SCI LTD
Bleckman, R F, Acem, I, van Praag, V M, Dorleijn, D M J, Verhoef, C, Schrage, Y M, Haas, R M L, van de Sande, M A J & the collaborative PERSARC research group 2022, ' Multimodality treatment of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) in the elderly ', European Journal of Surgical Oncology, vol. 48, no. 5, pp. 985-993 . https://doi.org/10.1016/j.ejso.2021.12.008
European Journal of Surgical Oncology, 48, 985-993. ELSEVIER SCI LTD

Introduction: This subgroup analysis of undifferentiated pleomorphic soft tissue sarcoma of the extremity (eUPS) from the PERSARC collaborative group aimed to achieve a more personalized multimodality treatment approach for primary eUPS in elderly pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51abbbdaf7cd60b7a381ed0cf900a768
http://www.scopus.com/inward/record.url?scp=85121383518&partnerID=8YFLogxK

Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients

Autor: Emma H.A. Stahlie, Evalyn E.A.P. Mulder, Sophie Reijers, Sara Balduzzi, Charlotte L. Zuur, Willem M.C. Klop, Bernies van der Hiel, Bart A. Van de Wiel, Michel W.J.M. Wouters, Yvonne M. Schrage, Winan J. van Houdt, Dirk J. Grunhagen, Alexander C.J. van Akkooi

Publikováno v: Critical Reviews in Oncology/Hematology, 175. ELSEVIER SCIENCE INC
Critical Reviews in Oncology/Hematology, 175:103705. Elsevier Ireland Ltd

Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates. The purpose of this systematic review

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afda418f16f959e55733a43646188c96
https://doi.org/10.1016/j.critrevonc.2022.103705

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model

Autor: Emma H A, Stahlie, Viola, Franke, Charlotte L, Zuur, Willem M C, Klop, Bernies, van der Hiel, Bart A, Van de Wiel, Michel W J M, Wouters, Yvonne M, Schrage, Winan J, van Houdt, Alexander C J, van Akkooi

Publikováno v: Cancer immunology, immunotherapy : CII. 70(8)

Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex type 1 virus and known as an effective oncolytic immunotherapy for injectable cutaneous, subcutaneous and nodal melanoma lesions in stage IIIB-IVM1a patients. This study set ou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::758fc3ba65dcae43577c78dff9fae9f6
https://pubmed.ncbi.nlm.nih.gov/33507342